Treats acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. ANDA 205696, held by Meitheal. Cytarabine.
As of Nov 16, 2026, ANDA 205696 (Cytarabine), held by Meitheal, was first approved by FDA on Jul 17, 2018, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Cytarabine Injection in combination with other approved anti-cancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and pediatric patients. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of Cytarabine Injection (preservative free preparations only) is indicated in the prophylaxis and treatment of meningeal leukemia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 17, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Cytarabine100MG/ML · injectable;injection | Cytarabine | Rx |
| Aug 25, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jul 17, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters